Facing Therapeutic Resistance to Maintenance Therapy: The Need for Novel Strategies in HER2+ mBC

Please visit answersincme.com/860/100850799-replay1 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by William J. Gradishar, MD, FASCO, FACP and Sara A. Hurvitz, MD, FACP. In this activity, experts in breast cancer discuss the evolving standard-of-care and emerging first-line maintenance strategies in HER2-positive metastatic breast cancer. Upon completion of this activity, participants should be better able to: Review the rationale for expanding the first-line maintenance therapy options for patients with HR-positive, HER2-positive mBC; and Summarize the latest evidence supporting novel first-line maintenance strategies in HR-positive, HER2-positive mBC.